# Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

> **NCT04251182** · PHASE2 · COMPLETED · sponsor: **T3D Therapeutics, Inc.** · enrollment: 250 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** 15mg T3D-959
- **DRUG:** 30 mg T3D-959
- **DRUG:** 45 mg T3D-959
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04251182
- **Lead sponsor:** T3D Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2023-01-20
- **Final completion:** 2023-02-17
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2024-07-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04251182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04251182, "Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04251182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*